在肺高血压中,N-终端前脑天然尿素的最小重要差异
Matthew R Lammi1, Sarah L Khan1, Youlan Rao2
1Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chest
|March 9, 2026
概括
在肺动脉高血压 (PAH) 和与间歇性肺病 (PH-ILD) 相关的肺高血压中,N终端前脑性尿性 (NT-proBNP) 的最小重要差异 (MID) 为48%. 实现这种NT-proBNP减少与更好的临床结果有关.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 生物标志物研究 生物标志物研究
背景情况:
- N-终端亲脑尿性 (NT-proBNP) 是评估肺高血压 (PH) 患者右心功能的一个关键生物标志物.
- 确定NT-proBNP的最小重要差异 (MID) 对于解释治疗疗效至关重要.
研究的目的:
- 确定NT-proBNP在肺动脉高血压 (PAH) 和与间歇性肺病 (PH-ILD) 相关的肺高血压变化的MID.
- 调查实现NT-proBNP MID是否与这些患者群体的改善临床结果有关.
主要方法:
- 使用了来自两个安慰剂对照试验的数据 (PAH的FREEDOM-EV,PH-ILD的INCREASE).
- 采用基于分布的方法来计算12周 (PAH) 和16周 (PH-ILD) 的NT-proBNP百分比变化的MID.
- 评估了MID成就与临床恶化事件 (PAH) 或6分钟步行距离 (6MWD) 改善 (PH-ILD) 之间的关联.
主要成果:
- 对于NT-proBNP变化的中位数MID是PAH和PH-ILD试验中的48%的改善.
- 达到MID的PAH患者显示,临床恶化的可能性降低了52% (HR,0.48;p=0.001).
- 达到MID的PH-ILD患者在6MWD (p=0.003) 中表现出40米的更大改善.
结论:
- 在NT-proBNP中减少48%代表了PAH和PH-ILD在临床上有意义的改善.
- 实现NT-proBNP MID与有利的临床结果密切相关,包括减少恶化事件和改善功能能力.
- 短期NT-proBNP变化可以为预后提供信息,并指导PAH和PH-ILD管理中的治疗决策.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
525
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
525
Pulmonary Hypertension: Classification and Pathogenesis
756
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
756
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
681
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
681
Transducer Mechanism: Enzyme-Linked Receptors
4.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.6K
Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
570
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
570


